Carlos García-Echeverría

Sanofi (France)

Publishes on PI3K/AKT/mTOR signaling in cancer, Chronic Lymphocytic Leukemia Research, Peptidase Inhibition and Analysis. 72 papers and 1.8k citations.

PubIndex Score15Top 85% · seniorHow it's scored

72Publications

1.8kTotal Citations

First publication: 1992First senior author: 1997

PI3K/AKT/mTOR signaling in cancer Chronic Lymphocytic Leukemia Research Peptidase Inhibition and Analysis Cell Adhesion Molecules Research Radiopharmaceutical Chemistry and Applications

Top publicationsby citations

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Carlos García-Echeverría, Doriano Fabbro et al.|Molecular Cancer Therapeutics|2008

Cited by 1.1k